PROTHENA CORPORATION P

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

18 Apr 2021 15:05:00 By Nasdaq GlobeNewswire

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021

15 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

07 Apr 2021 10:47:03 By Nasdaq GlobeNewswire

Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021

08 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021

24 Feb 2021 16:05:01 By Nasdaq GlobeNewswire

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

11 Feb 2021 08:00:01 By Nasdaq GlobeNewswire

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05 Feb 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th

04 Feb 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA

01 Feb 2021 16:15:00 By Nasdaq GlobeNewswire